Phase-Changing Matrix for 3D Organoid Culture with Mesenchymal Stem Cells
Summary
The USPTO published Application US20260092254A1 claiming a composition for three-dimensional cell and organoid culture comprising a phase-changing matrix with partially ordered polypeptide encapsulating bone-marrow derived or adipose-derived mesenchymal stem cells. The application was filed on September 21, 2023 (Application No. 19113814). This publication provides public notice of the claimed invention for examination purposes.
What changed
Application US20260092254A1 discloses a composition for three-dimensional cell and organoid culture comprising a phase-changing matrix of partially ordered polypeptide encapsulating mesenchymal stem cells derived from bone marrow or adipose tissue. The matrix contains structured and disordered domains, includes RGD sequences for chemical interaction, and forms a porous network when heated above its transition temperature. The application covers C12N classifications related to cell culture and A61L biomedical materials.
This patent application publication serves as prior art notice and does not impose compliance obligations on any party. Companies developing organoid culture systems, biomaterials for 3D cell culture, or mesenchymal stem cell therapies should review the claimed scope to assess potential freedom-to-operate implications. No action is required by compliance teams as this is an examination publication, not an issued patent or regulatory requirement.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
FULLY DEFINED MATRICES FOR ORGANOID CULTURE
Application US20260092254A1 Kind: A1 Apr 02, 2026
Inventors
Stefan ROBERTS
Abstract
The present disclosure relates to a composition for three-dimensional cell and/or organoid culture, comprising a phase-changing matrix comprising a partially ordered polypeptide, and a plurality of cells encapsulated in the matrix. In embodiments, the plurality of cells comprises one or more cell types, including at least one cell type selected from the group consisting of: bone-marrow derived mesenchymal stem cells and adipose-derived mesenchymal stem cells. In embodiments, the one or more cell types comprises mesenchymal stem cells, the partially ordered polypeptide comprises at least one chemically-interactive sequence such as arginylglycylaspartic acid (RGD) sequence, the matrix forms a porous network when heated above a transition temperature, and the partially-ordered polypeptide comprises a plurality of structured domains, and a plurality of disordered domains.
CPC Classifications
C12N 5/0068 A61L 27/3834 C12N 5/0012 C12N 5/0062 C12N 5/0652 A61L 2400/06 C12N 2533/50 C12N 2535/00
Filing Date
2023-09-21
Application No.
19113814
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Biotech (C12N) publishes new changes.